Every person is unique. We can clearly see this within the more than one million genomic profiles from 70 different countries analyzed by our technology.
Third party sequencing services can enable increased access to NGS testing, but if institutions do not receive access to the raw data it can limit the insights they can gain. Doing the data analysis in house can allow you to harness the power of genomic data to reveal relevant variants.
Next generation sequencing has greatly enhanced our power for identifying mutations associated with myeloid malignancies. However, accurate and timely detection of complex variants can be challenging.
The field of precision medicine continues to evolve but remains steadfast in its goal to provide the right treatment to the right patients at the right time. This blog examines the evolution of precision medicine and how we can achieve its promise.
Whole exome sequencing has the potential to accelerate the diagnosis of rare diseases, but without the right tools, achieving comprehensive coverage and sifting through tens of thousands of variants is a challenge.
Microsatellite Instability: how do microsatellites mutations correlate with cancer?
Increased access to genomic testing can help fulfill the promise of making precision medicine accessible to all, but the upfront investment required for institutions to start their own sequencing labs remains a barrier. This challenge can be overcome by using sequencing service.
Learn about the impact of HRD in cancer development, how HRD status may predict sensitivity to certain treatments, and the different HRD testing methods available.
What are mitochondria, why do they cause disease, and how can we analyze their genome?
Humans being replaced by computers is a common theme in TV shows, movies, books and more. But unlike what we often see in fiction, artificial intelligence (AI) doesn’t replace the human factor in medicine.